Drug Trial Radar · NCT05705271
A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 8, 2023
Primary completion
Jul 3, 2025
Study completion Jul 3, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 2 diabetes (T2D). In people with T2D, the body does not make enough of a hormone called insulin or does not use the insulin well enough. Insulin's role is to regulate the amount of glucose (sugar) in the blood. Too much blood sugar can cause damage to the kidneys over time. Consequently, CKD can happen as one of the complications of T2D. The study treatment finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of the mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Finerenone is already available in several countries for doctors to prescribe to people with CKD and T2D. In addition, it was recently approved in India with a request to specifically gather information on finerenone therapy in Indians. The main purpose of this study is to learn how safe finerenone is in Indian people with CKD and T2D. For this, the researchers will count the number of participants who have: * medical problems after taking finerenone * abnormal high levels of potassium in the blood (called hyperkalemia). Researcher will also count the number of participants in whom hyperkalemia: * leads to stop of finerenone treatment * requires treatment to filter wastes and water from the blood * leads to a hospital stay. Doctors keep track of all medical problems that happen in studies, even if they do not think the medical problems might be related to the study treatments. In addition, the study team will collect more data about how well finerenone works in Indian people with CKD and T2D under real world setting. Working well means that the treatment can prevent the following from happening: * reduced kidney function over a period of at least 4 weeks * death from renal problems * death due to conditions affecting the heart and blood circulation * heart attack (blocked blood flow to the heart) * hospital stay due to a condition which occurs when the heart does not pump blood as well as it should * changes of the albumin and creatinine levels in urine. The participants will be in the study for approximately 20 months. They will take the study treatment once daily as a tablet by mouth for 18 months. In the study, 9 visits to the study site are planned. During the study, the study team will: * take blood and urine samples * do physical examinations * check the participants' overall health * do pregnancy tests * examine heart health using electrocardiogram ECG * check vital signs. About 30 days after the participants take their last treatment, the study doctors and their team will check worsening of reported underlying diseases: * damage to the blood vessels in the tissue of the retina at the back of the eye, as a result of diabetes mellitus * a long-term condition where the heart does not pump blood as well as it should with symptoms such as shortness of breath, tiredness and ankle swelling * heart attack (blocked blood flow to the heart) * death due to conditions affecting the heart and blood circulation or * hospital stay.
Conditions
- Chronic Kidney Disease
- Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY94-8862)Drug
Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first finerenone treatment date up to 30 days after the last treatment date
- Number of participants with hyperkalemia eventsTime frame: Up to 19 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Nizam's Institute of Medical Sciences (NIMS)
Hyderabad, India
Bhate Hospital
Karnataka, Belagavi, India
Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
Nadiād, Gujarat, India
Accord Superspeciality Hospital
Faridabad, Haryana, India
Kempegowda Institute of Medical Sciences Hospital & R C
Bangalore, Karnataka, India
Christian Medical College
Vellore, Kerala, India
Global Hospital-Super Speciality And Transplant Centre
Mumbai, Maharashtra, India
Lancelot Medical Centre
Mumbai, Maharashtra, India
Dr Balabhai Nanavati Hospital
Mumbai, Maharashtra,, Maharashtra, India
PSRI Institute of Renal Sciences
New Delhi, National Capital Territory of Delhi, India
Vardhman Mahavir Medical College & Safdarjung Hospital (VMMC-SJH)
New Delhi, National Capital Territory of Delhi, India
All India Institute of Medical Sciences
Bhubaneswar, Odisha, India
Jawaharlal Institute Of Postgraduate Medical Education and R
Gorimedu, Puducherry, India
Government Stanley Medical College and Hospital
Chennai, Tamil Nadu, India
M.V. Hospital & Research Centre 314/30
Chowk Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
Lucknow, Uttar Pradesh, India
Medica Superspecialty Hospital
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.